Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus
Status:
Withdrawn
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The investigators center has also analyzed data over the last 7 years from deceased donor
(DD) and living donor (LD) kidney transplant recipients who were randomized into 3
immunosuppressive arms between 2000 and 2001. Thus the goal of the investigators study is to
reduce the toxic effects of traditional immunosuppressive regimens involving high-dose
calcineurin inhibitor agents by comparing low-dose TAC-MYF with low-dose TAC and de novo SRL
regimens. In order to minimize exposure to TAC, the investigators center has previously shown
favorable outcomes using combination Thymoglobulin and Zenapax (Daclizumab) for
anti-lymphocyte induction in the investigator population of patients.